Almost everyone gets these. Most people manage them wrong in the same few ways β paracetamol in dribbles instead of one real ibuprofen dose taken early; daily painkillers quietly crossing the line where they become the cause of the headaches they were bought to fix; the occasional mild migraine being treated as plain tension. Get the rules right and the dull-head afternoons drop sharply. Miss them and the occasional pattern quietly grades into the daily one. Cheap to act on, and mostly a matter of knowing what counts and when.
The lay name suggests a literal clench, and that model has been dead for thirty years. Surface-EMG studies in the 1990s showed that people with tension-type headache do not, in fact, sit with sustained muscle contraction between attacks Bendtsen & Jensen 2006. What is happening is closer to a sensitisation of the small pain nerves in the muscles around the skull β across the forehead and temples, along the jaw, around the base of the head, and down the slope from neck to shoulder. Those nerves get primed to fire at lower thresholds. Pressing those muscles reproduces the headache; the more often the headache happens, the more sensitised they get.
For occasional, episodic attacks that is most of the story. For people whose headaches creep up to half the month or more, a second layer comes in: the spinal-cord relay that handles those nerves' input also turns up its gain, and the pain pathways start firing for less reason Bendtsen 2000. This is why drugs that act on the central pain system β notably amitriptyline β work better than purely physical measures for the chronic version, while the occasional attack mostly answers to one well-timed painkiller.
Posture and screen-bound habit feed into this as one input, not the whole story. Forward-head posture is more common in chronic sufferers than in matched controls FernΓ‘ndez-de-las-PeΓ±as et al. 2006; tender spots in the suboccipital muscles, the upper trapezius and the temple muscle are present in the large majority of chronic cases CouppΓ© et al. 2007. Stress, jaw clenching, broken sleep and skipped meals are the other usual loading inputs. They are triggers feeding a sensitised system; fixing one of them helps in proportion to how much it was contributing.
What actually works
The evidence base is one of the more settled in headache medicine. For an active attack, a real dose of an anti-inflammatory taken early is the move: ibuprofen 400 mg is the most-studied option, with about one in seven readers reaching pain-free at two hours over what placebo would deliver, across the Cochrane review of nine randomised trials Derry et al. 2015. Paracetamol works, but works less β at 1000 mg it edges placebo on the same hard endpoint, and not by much Stephens et al. 2016. The split between felt better and pain gone matters here: either drug will dull the attack; the anti-inflammatory is the one that ends it.
For people in the frequent zone β two days a week or more β the strongest preventive evidence is for amitriptyline, an old, cheap drug originally sold for depression but used at lower doses for nerve-pain conditions. A pooled analysis of trials found roughly half the headache days disappear over months of treatment, with the effect size building from week to week Jackson et al. 2010. The European specialist guideline lists it first-line for this reason Bendtsen et al. 2010. Biofeedback β learning to relax the head-and-neck muscles using a tone or visual signal driven by your own muscle activity β matches drug-grade effect sizes across more than fifty trials, and the gains hold at follow-up Nestoriuc et al. 2008.
Acupuncture has Cochrane-level evidence for tension-headache prevention: roughly half of treated patients see a meaningful drop in headache days, against about a quarter in no-treatment comparison Linde et al. 2016. Botulinum toxin, which works for chronic migraine, does not work for chronic tension-type headache; multiple placebo-controlled trials have shown no benefit, and the specialist guideline explicitly advises against it Bendtsen et al. 2010.
Three things most people get wrong
The painkiller you take twice a week, with a real attack, is fine. The painkiller you take to head off the dull pressing on most days is, past a threshold the labels do not name, the cause of the dull pressing on most days. Medication-overuse headache β a near-daily headache state driven by frequent analgesic use in someone who already had headaches β runs on a documented count: simple painkillers on fifteen or more days a month for more than three months, or combination products (the painkiller-plus-caffeine ones especially), triptans, or opioids on ten or more days a month Diener et al. 2016. The trap is invisible from inside, because it presents as "my headaches are getting worse, I need to keep medicating." The fix is the opposite move: stop the offending medication and ride out the rebound. Roughly half of overusers revert to their original episodic pattern after a clean withdrawal Diener et al. 2016.
The second wrong-thing is the lay name. "Tension" suggests literal sustained muscle clench, which the EMG studies of the last thirty years have not found Bendtsen & Jensen 2006. The headache is real; the muscles are sensitised, not contracted. This is why an entire commercial category β posture braces, neck stretchers, blue-light glasses sold for "screen headaches," tension pillows β shows so little signal in headache trials. The implied mechanism was retired before the products were invented.
The third: what people call a "tension headache" is, on careful interview, often a mild or moderate migraine that hasn't been correctly identified. If a headache is one-sided, throbs rather than presses, brings nausea, makes light or sound briefly unbearable, or knocks out the rest of the day β that is migraine territory, and it answers to a triptan, not a bigger anti-inflammatory. The corollary: an honest answer to "what does the bad version of this feel like" matters more than the label you've been using.
The slow slide if you don't act
Episodic tension-type headache has a documented trajectory into the chronic version when it is poorly handled. The two main drivers are well-established: medication overuse layered on top of the original pattern, and the cumulative sensitisation of the central pain pathways that comes from headache after headache being processed without recovery Diener et al. 2016 Bendtsen 2000. The slow version reads like this: a stressful quarter brings four headache days a week and a daily painkiller; the painkiller becomes the new floor; the headaches don't ease when the stress does; you become a person who "just gets headaches"; five years pass.
What that looks like day to day β and the Global Burden of Disease data agree on this Stovner et al. 2018 β is a steady drag on the parts of life that are sensitive to a half-functional afternoon. The Tuesday meeting goes worse than it should. The evening you wanted for someone you love goes into bed early instead. A partner notices you've been looking tired for months, then for a year. People at work stop including you in things that need someone sharp at 4pm. Anxiety and depression rates run measurably higher in people with chronic tension-type headache than in those without it; causation runs both ways, and reversing the headache pattern lifts the mood load with it.
The chronic version is substantially harder to reverse than to prevent. The window for the cheap intervention β the right acute dose, the honest count of analgesic days, the call to a clinician when the count climbs past two days a week β is the episodic stage. After chronification the road back runs through medication withdrawal, weeks of rebound, and months of preventive treatment. It works; it is just not free.
The protocol
For an attack, take a real anti-inflammatory dose early β within the first thirty minutes of the headache becoming noticeable, before you spend two hours hoping it'll go away on its own. The earlier and the bigger the first dose, the cleaner the resolution.
Then keep an honest count. Headache days per month is the number that matters β write them on a calendar or in a notes app for a quarter. Below four days a month: keep doing what you're doing. Four to eight: tighten the lifestyle inputs β sleep regularity, water through the day, eye-strain breaks for screen workers, watch jaw clenching at night β and stay below the medication-overuse thresholds. Eight or more headache days a month, and it is worth talking to a clinician about prevention.
The lifestyle layer matters but is supporting, not load-bearing. Modest evidence backs regular water through the day reducing headache severity in chronic-headache cohorts Spigt et al. 2012, plus regular sleep hours and breaking up screen time. These are the rails that keep the system from sliding back; they are not, on their own, the fix for a frequent or chronic pattern.
When it isn't tension headache
Tension-type headache has a recognisable shape: bilateral, pressing, mild-to-moderate, not aggravated by climbing stairs, no nausea, no aura. The everyday dull band at the end of a screen-bound day is not the worry. The call is between recognising your usual pattern and noticing when something deviates from it.
Where this goes wrong
- Chasing relief with the wrong dose, on the wrong drug, at the wrong time. Paracetamol every few hours through the day in dribbles performs worse on an attack than a single well-timed ibuprofen Derry et al. 2015. Half-doses taken cautiously perform worst of all.
- Crossing the medication-overuse line without noticing. The threshold is days per month, not pills per attack β one pill on fifteen days a month is over the line. People watch the pill count and miss the day count.
- Treating an undiagnosed migraine as plain tension. A "tension headache" that nauseates you or shuts down the rest of the day is not a tension headache; the answer there is a migraine workup, not a bigger anti-inflammatory.
- Quitting amitriptyline at week two. The drug needs four to eight weeks to show full effect, and the early side effects (dry mouth, sedation) often peak before the headache benefit lands Jackson et al. 2010. The trial that "didn't work" usually wasn't a fair trial.
- Buying the tension-product market. Posture braces, neck stretchers, blue-light glasses sold for screen headaches, "tension" pillows β the implied mechanism (literal sustained muscle clench) was retired in the 1990s and these products show little signal in headache trials Bendtsen & Jensen 2006. Spend the money on a real workstation setup, or on a course of biofeedback, instead.
What changes when you act on this
Week one: an attack ends in the time it used to take to half-end, because the dose was right and went in early β not the paracetamol-in-dribbles version of either. The afternoon you wrote off comes back to you. The count starts.
Month three: you have an honest tally of headache days. If you were already in the four-or-fewer-a-month zone, the rules have kept you there. If you were higher, you are three months into amitriptyline at a tolerable nightly dose, or three months into biofeedback, and the count is dropping. The literature's expectation is that headache days roughly halve over months on either route, and that is the experience of most people who finish the course Jackson et al. 2010 Nestoriuc et al. 2008.
Year one: the social shift. The version of you that masked an afternoon and then a meeting with a dull pressing forehead becomes the version that just had a normal Tuesday. A partner stops noticing you look tired by Wednesday. People at work stop quietly routing the late-afternoon hard problems around you. You have stopped describing yourself as someone who "just gets headaches," because you have an honest count and the count is small Stovner et al. 2018.
None of this is a cure. Tension-type headache is recurrent and the entry stays a page you can revisit. The difference is between occasional, recognised, treated correctly and daily, accepted, escalating β and the slide from the first to the second is exactly what the rules above are there to interrupt.
Adjacent terrain worth knowing about: migraine β a separate disorder with its own drug class, often confused with tension-type when mild; the cleanest tell is throbbing-plus-disabling-plus-nausea. Cluster headache β rare, severe, one-sided, around the eye; an emergency-recognition pattern. Cervicogenic headache β headache arising from the upper neck joints, easy to confuse with chronic tension-type when neck pain dominates. Medication-overuse headache stands on its own for readers who suspect they are already inside the trap and need the withdrawal playbook. And the general lifestyle layers this entry leans on β regular sleep, hydration, screen ergonomics, stress management β each have their own page where the depth lives.
Substance and claimed effects
Tension-type headache (TTH) is the most common primary headache disorder and, by hours lost, the single largest cause of headache-related disability worldwide Stovner et al. 2018. The phenomenology defined by the International Classification of Headache Disorders, 3rd edition is consistent: bilateral, pressing or tightening (non-pulsating) pain of mild to moderate intensity, lasting 30 minutes to 7 days, not aggravated by routine physical activity, and without nausea β though mild photophobia or phonophobia (but not both) may be present IHS 2018. ICHD-3 separates infrequent episodic (<1 headache day/month), frequent episodic (1β14 days/month), and chronic (β₯15 days/month for >3 months) subtypes; the entry covers all three, since the management decisions diverge sharply at the chronic threshold. Claimed effects across catalogue dimensions: short-term health (pain frequency and intensity are the primary endpoints), focus (active-headache cognitive load), mood (chronic-pain comorbidity), energy (post-headache fatigue), and sleep (bidirectional with insomnia). No claimed mortality effect β TTH is not life-shortening; the longevity issue is purely the differential-diagnostic question of distinguishing it from a secondary headache that is life-threatening.
Evidence by addressing question
mechanism
Peripheral lens. The most consistently observed abnormal finding in TTH is increased tenderness of the pericranial muscles β frontalis, temporalis, masseter, sternocleidomastoid, trapezius, and the suboccipital group β on manual palpation, and the tenderness increases with headache intensity and frequency Bendtsen & Jensen 2006. Active myofascial trigger points in the suboccipital, upper trapezius, and temporalis muscles are present in the large majority of chronic TTH patients and reproduce the patient's typical headache pattern on palpation CouppΓ© et al. 2007. Forward head posture and reduced cervical range of motion are over-represented in chronic TTH, with a measurable correlation between posture and headache frequency in a blinded, controlled study FernΓ‘ndez-de-las-PeΓ±as et al. 2006. The original "sustained low-grade muscle contraction" model of the 1960sβ1980s did not hold up on surface-EMG measurement β TTH patients do not show sustained contraction in the muscles between headaches β so the modern peripheral model is one of nociceptor sensitization from chronic mechanical and chemical irritation of myofascial tissue, not contraction per se.
Central lens. Chronic TTH shows central sensitization β second-order neurons in the trigeminal nucleus caudalis and dorsal horn become hyper-responsive to peripheral input, and descending pain-modulatory pathways are attenuated Bendtsen 2000. Pressure-pain thresholds measured at the temporalis and elsewhere are reduced in chronic TTH compared with healthy controls and with episodic TTH, and the reduction extends to body sites distant from the head β a fingerprint of central, not peripheral, sensitization. This is the load-bearing model for why chronic TTH responds to centrally-acting prophylactics (amitriptyline) far better than to peripheral interventions, and why pure peripheral approaches (massage, posture correction alone) cap out at modest effect sizes in the chronic subtype.
Practice lens. The current European Federation of Neurological Societies guideline frames TTH as a multifactorial disorder with both peripheral and central contributions, weighted toward peripheral for episodic and toward central for chronic Bendtsen et al. 2010.
evidence
The epidemiology is settled. One-year prevalence in adults runs ~38β42% globally; lifetime prevalence is higher still, reaching ~70% in some European cohorts; chronic TTH affects ~0.5β3% of adults depending on the population Stovner et al. 2018. The Global Burden of Disease 2016 analysis identified TTH as the third most prevalent disease in the world and a leading non-fatal contributor to years lived with disability when summed across episodes.
Acute pharmacological treatment is well-trialed. Ibuprofen at doses of 400 mg versus placebo shows a number-needed-to-treat (NNT) of ~7 for pain-free at 2 hours in the Cochrane review of nine RCTs (n > 3,000) β a real but modest absolute effect Derry et al. 2015. Paracetamol at 1000 mg shows an NNT of ~22 for pain-free at 2 hours, with a marginal but statistically detectable advantage over placebo Stephens et al. 2016. The two reviews together establish that NSAIDs are first-line and outperform paracetamol on the harder endpoint of pain-free (as opposed to pain-relieved), and that no acute analgesic produces a transformative response β most attacks need some medication assistance, but the patient remains aware of having had a headache. Aspirin sits between ibuprofen and paracetamol on efficacy.
For prevention of frequent/chronic TTH, amitriptyline is the best-evidenced agent. Jackson et al.'s meta-analysis of tricyclics across chronic headache (TTH and chronic migraine) found a ~50% reduction in headache frequency on amitriptyline versus placebo at doses of 10β75 mg/day, with effect size growing over months of treatment Jackson et al. 2010. Mirtazapine and venlafaxine have positive but smaller-trial evidence and are second-line per EFNS Bendtsen et al. 2010. Onabotulinumtoxin A is not effective for chronic TTH in placebo-controlled trials β a striking divergence from chronic migraine, where it is approved β and the EFNS guideline explicitly advises against it.
For non-pharmacological prevention: EMG biofeedback for TTH has a Cohen's d of ~0.7 across 53 trials in Nestoriuc et al.'s meta-analysis, with effects maintained at follow-up Nestoriuc et al. 2008. Acupuncture has Cochrane-grade evidence of benefit for frequent episodic and chronic TTH, with at least 50% headache-day reduction in about half of treated patients (vs ~25% with sham/no treatment) Linde et al. 2016. Aerobic exercise has smaller RCTs supporting frequency reduction; the EFNS guideline lists it as a reasonable adjunct.
protocol
For acute (episodic) attacks the evidence-based first move is an NSAID, typically ibuprofen 400β600 mg or naproxen 500β1000 mg, taken early in the attack Derry et al. 2015 Bendtsen et al. 2010. Paracetamol 1000 mg is second-line when NSAIDs are contraindicated Stephens et al. 2016. Combination products that bundle analgesic + caffeine are effective on attack-level endpoints but carry the highest medication-overuse risk and the EFNS guideline cautions against routine use. Opioids and barbiturates have no place in TTH treatment β they perform no better acutely and substantially worsen chronification risk.
For prevention (frequent episodic, β₯2 days/week, or chronic), the EFNS first-line is amitriptyline, starting 10 mg nightly and titrating over weeks to 30β75 mg against tolerability and effect, with a meaningful response typically requiring 4β8 weeks Jackson et al. 2010 Bendtsen et al. 2010. EMG biofeedback or cognitive-behavioural therapy is an evidence-equivalent non-pharmacological prevention strategy Nestoriuc et al. 2008.
contraindications
This is a condition entry rather than a substance, so "contraindications" recasts as red flags requiring escalation. The classical mnemonics (SNOOP, SNNOOP10) converge on the same list: sudden thunderclap onset, fever with neck stiffness, focal neurological deficits, new onset after age 50, immunosuppression or active cancer, headache that worsens with Valsalva or wakes the patient from sleep, headache with personality change. None of these features fit TTH; any of them mandates same-day workup for subarachnoid haemorrhage, meningitis, mass lesion, or temporal arteritis. Acute-medication contraindications follow the agent: NSAIDs and active peptic ulcer, advanced renal disease, bleeding diathesis; paracetamol and severe hepatic impairment.
misconceptions
The most commercially-leveraged misconception is that "tension headache" is caused by literal sustained muscle contraction β this drives the entire market for posture pillows, neck stretchers, and ergonomic gadgets sold to headache sufferers. Surface-EMG studies in the 1990s and onward show TTH patients do not exhibit sustained pericranial contraction between attacks; the abnormality is muscle tenderness and nociceptor sensitization, not contraction per se Bendtsen & Jensen 2006. The IHS retained the historic name because it is entrenched, not because it remains mechanistically accurate.
The second large misconception: that frequent OTC analgesic use is harmless. Medication-overuse headache is the leading iatrogenic mechanism by which episodic TTH becomes chronic β taking simple analgesics on β₯15 days/month or combination/triptan/opioid products on β₯10 days/month for >3 months produces a chronic daily headache state that does not remit without withdrawal of the offending agent Diener et al. 2016. Patients and primary-care clinicians both substantially underestimate this threshold; the practical implication is that any reader using analgesics for headache twice a week or more is in the at-risk zone.
A third misconception: that what most people call a "tension headache" is, on careful diagnostic interview, often a mild or untreated migraine. Population surveys consistently find under-diagnosis of migraine in patients self-labelling tension headache, and the implication is that an episodic headache that genuinely disables β that fits photophobia, nausea, or unilateral throbbing β needs migraine-class treatment, not stronger NSAIDs.
practicalities
Simple analgesics are inexpensive and OTC. Amitriptyline is off-patent and cheap; the friction is tolerability β anticholinergic side effects (dry mouth, sedation, weight gain, constipation, orthostasis) cap adherence in many patients and force discontinuation in roughly 20β30% across trials Jackson et al. 2010. Biofeedback access is uneven (more common in Germany and parts of the US than the UK and most of LMIC settings); the evidence base is among the strongest non-pharmacological in headache medicine but availability does not match. Acupuncture, where covered or affordable, has Cochrane-grade evidence as noted but a course is 6β10 sessions Linde et al. 2016.
failure-modes
Three predictable failure modes: (1) escalating analgesic frequency to chase relief, progressing into medication-overuse headache Diener et al. 2016; (2) treating an undiagnosed migraine as a tension headache and underdosing (a triptan would resolve attacks that NSAIDs only blunt); (3) abandoning amitriptyline at 2β3 weeks for "not working" when it requires 4β8 weeks for full effect, or at low dose for tolerability rather than titrating, then concluding prophylaxis "didn't work" Jackson et al. 2010. A fourth β purely lifestyle approaches in chronic TTH where central sensitization is established β caps effect at modest reductions; the chronic subtype needs centrally-active prophylaxis.
stakes
Chronic TTH (β₯15 days/month) is associated with markedly elevated rates of comorbid anxiety and depression, lost work days, and impaired sleep Stovner et al. 2018. The Global Burden of Disease estimates rank tension-type headache among the leading causes of years lived with disability worldwide despite the per-attack burden being smaller than migraine β sheer prevalence does the work. Episodic TTH that is poorly managed has a documented trajectory into chronic TTH via medication overuse, sleep disruption, and the cumulative central-sensitization mechanism, and the chronic state is substantially harder to reverse than to prevent Diener et al. 2016 Bendtsen 2000.
payoff
Recognising that an episodic TTH is exactly that β and treating it with a single early NSAID dose rather than escalating frequency β keeps the headache at episodic and the analgesic count low. Adding biofeedback or amitriptyline at the frequent-episodic stage reduces headache days by ~50% in the trials cited above Jackson et al. 2010 NestoriucEtAl2008 β over months, that translates to whole weeks of pain-free time recovered each year and proportional reductions in lost work and pain-driven mood disturbance.
history
The "muscle contraction headache" concept dominated 1960sβ1980s neurology and survives in the lay name "tension headache." The IHS renamed it to tension-type headache in 1988 to flag the contraction model as not yet proven, and the third edition (2018) retains that scepticism: the name endures by convention while the mechanism is now framed as multifactorial peripheral-plus-central IHS 2018. The term "tension" is therefore a historical artefact, not a mechanistic claim.
out-of-scope
Migraine (treated separately because triptans, gepants, and the migraine-specific prophylactics are off-evidence for TTH); cluster headache (different phenotype, different drugs); the secondary headaches called out under contraindications (each warrants its own emergency-recognition entry); cervicogenic headache (a related but distinct musculoskeletal headache arising from upper cervical spine pathology). Hydration as a general health entry; sleep hygiene; screen ergonomics β referenced here, but the depth lives in adjacent entries.
The credibility range
Optimist case. TTH is the most-studied primary headache after migraine, and the evidence base supports a coherent stack: NSAIDs work acutely Derry et al. 2015, amitriptyline works prophylactically Jackson et al. 2010, biofeedback works as well as drugs in head-to-head trials Nestoriuc et al. 2008, and the mechanism β peripheral pericranial sensitization in episodic, central sensitization layered on top in chronic β is internally consistent and matches the dose-response of treatments. A reader who follows the EFNS playbook (NSAID early in attack; amitriptyline if >2 days/week of headache; biofeedback alongside; vigilance against MOH) has a high probability of staying episodic and avoiding the chronic trap.
Skeptic case. The diagnostic boundary between TTH and migraine is fuzzy and self-report-driven; population surveys repeatedly find that what people call "tension headache" is, on careful interview, often mild migraine β meaning many of the "TTH treatment success" stories may be untreated migraine responding less than it would to migraine-specific drugs. The acute-treatment effect sizes are modest (paracetamol NNT 22 for pain-free is borderline trivial). Amitriptyline's tolerability is poor enough that real-world adherence is far below trial adherence. The "muscle tension" branding has driven a massive industry of unproven posture / ergonomic / massage products whose effect sizes are at or below placebo. And the literature is heavily anchored in European cohorts of presenting patients, which over-represents chronic and frequent episodic subtypes β most people with rare episodic TTH never enter a study.
Author's call. The evidence is strong enough to act on (evidence 4): TTH is real, treatable, and the management algorithm holds. The single most actionable insight is the medication-overuse mechanism β the readers most at risk are precisely those treating headaches "responsibly" with daily/most-day OTC analgesics, and the threshold for harm is lower than they assume. Controversy is modest (2) β the field largely agrees on the algorithm; the open questions (TTH-vs-migraine boundary, mechanism granularity, role of psychiatric comorbidity) do not destabilise treatment recommendations.
Stakeholder and incentive map
- OTC pharmaceutical industry. Combination analgesics (analgesic + caffeine, sometimes + codeine in some markets) drive the largest revenue in the headache space and are exactly the products most implicated in medication-overuse headache. Manufacturer messaging emphasises rapid relief; downside framing is muted. The MOH risk is the single most under-communicated piece of evidence in this category.
- Ergonomics / "tension" product market. Posture braces, neck stretchers, neck pillows, blue-light glasses for "screen headaches," cervical traction devices. The lay name of the disorder is itself a marketing channel. Effect sizes for these products in controlled trials are small to nil; the implied mechanism (the resolved "literal muscle contraction" model) is decades out of date.
- Neurology and headache specialists. Disincentive against expensive workup for typical TTH (presentation is reassuring; imaging is not indicated absent red flags); incentive toward identifying the chronic and MOH cases, where prophylaxis and withdrawal are clinically high-value.
- Physiotherapy / manual therapy / acupuncture. Mixed: real evidence base for biofeedback and acupuncture in TTH; less for generic massage. Commercial interest is to bundle TTH into broader "headache and neck pain" services where evidence-base attribution gets fuzzy.
- Eye-care industry. Real but small role β uncorrected refractive error and accommodation/convergence disorders contribute to a subset of "tension" headaches; the commercial overreach is blue-light coatings, which have no headache evidence base.
Population variability
Female-to-male ratio is ~5:4 for episodic TTH and slightly higher for chronic β smaller than the migraine 3:1 ratio but consistent across populations Stovner et al. 2018. Onset peak is the 30sβ40s, with declines after 60 unlike migraine which tends to attenuate at menopause. Chronic TTH clusters with chronic pain comorbidities (low back pain, fibromyalgia) and with anxiety and depression, with the direction of causation bidirectional β sleep disruption and psychiatric comorbidity raise risk; chronic headache also raises risk of mood disorder. Adolescents and children get TTH at notable rates (10β25%); paediatric treatment leans more heavily non-pharmacological. Pregnancy: episodic TTH often improves; amitriptyline carries a small but documented risk and decisions are clinician-led. Older adults presenting with new TTH-like headache need closer workup β new headache after 50 is itself a red flag for secondary causes (temporal arteritis especially).
Knowledge gaps
The TTH-vs-mild-migraine boundary remains poorly resolved at the population-screening level; better diagnostic tooling that distinguishes them outside a specialist clinic would change a lot of management decisions. Long-term prophylaxis trials beyond 6β12 months are sparse β what amitriptyline's net effect over 5 years looks like is not well-characterised, including whether chronic-TTH patients can taper off. The role of central sensitization-targeted drugs newer than amitriptyline (gabapentinoids, SNRIs at neuropathic-pain doses) is under-studied in TTH specifically. And the lifestyle factors named in the topic brief β posture, eye strain, hydration β each have a thin to modest evidence base for headache effect; the practical "common sense" advice is not as well-trialed as the pharmacological algorithm.
Category call. Placed under msk-conditions rather than mental, medical, or other. Rationale: the mechanism the article rests on is pericranial muscle sensitisation plus central sensitisation downstream of it; posture and pericranial tenderness are the load-bearing physical findings; the differential against migraine, cluster, and cervicogenic headache all sit in the same musculoskeletal-adjacent neighbourhood. Stress is a major trigger, not the mechanism, so mental would mislabel the centre of gravity.
Narrowing relative to the brief. The topic description named "muscle tension, posture, stress, eye strain, sleep, hydration, and medication-overuse risk." All seven are touched in the article. The one that gets less depth than the brief might imply is eye strain: the published evidence linking uncorrected refractive error or accommodation problems to TTH specifically (as opposed to ocular discomfort) is thin and would not support a dedicated paragraph at the article's quality bar. It is handled as one input feeding the sensitisation model (mechanism) and as the "eye-strain breaks for screen workers" lifestyle rail (protocol). The blue-light-glasses point in misconceptions and failure-modes does double duty as a quiet correction of the eye-strain-product market.
Action verb call. Picked respond over know. The entry is a centre-of-gravity respond entry β what to do during an attack, when to escalate, and where the medication-overuse line is β with awareness content (red flags, mechanism) as the supporting layer. Cadence as-needed follows from that.
Rating difficulties.
- applicability = 5. Leans on the spec Β§6 guardrail that avoidance and emergency-recognition content score on the wider decision audience, not the current-doer count. TTH itself is universal (~40% one-year prevalence; ~70% lifetime per Stovner et al. 2018), but the MOH-avoidance and red-flag-recognition content extends relevance to essentially every adult who has ever reached for a painkiller for head pain.
- health_short_term = 4. Borderline 3/4. Held at 4 because the MOH-avoidance insight alone is a meaningful day-to-day QoL lift for a sizeable fraction of readers β the frequent-but-not-yet-chronic group, which is where the lever bites hardest.
- focus = 3, mood = 2. These track active and chronic headache load rather than the substance giving a focus/mood lift in the way exercise does. Scored on what reversing the headache pattern returns to the reader, with the chronic-comorbidity literature as the anchor.
- controversy = 2. The mechanism literature is genuinely contested at the peripheral-vs-central balance, and the TTH-vs-mild-migraine boundary is unresolved, but the management algorithm is not β hence modest, not high.
Separate-entry candidates.
- Medication-overuse headache β substantial enough to warrant its own entry, with the withdrawal playbook as the centre of gravity for readers who are already inside the trap and need more than the prevention framing this entry gives them.
- Migraine β out-of-scope here; needs its own page covering triptan/gepant treatment, prophylaxis, aura, and the diagnostic boundary against TTH from the other direction.
- Cluster headache β rare but emergency-recognition-worthy; scored against the broad awareness audience per spec Β§6.
- Cervicogenic headache β distinct upper-cervical-spine origin, often confused with chronic TTH when neck pain dominates.
- Biofeedback as a discrete intervention β EMG biofeedback in particular has Cochrane-grade evidence across headache disorders; worth its own page rather than only appearing as a bullet inside TTH and migraine entries.
- Amitriptyline at low dose for pain β the cross-cutting role in TTH, chronic migraine, fibromyalgia, and neuropathic pain probably justifies a dedicated page rather than recurring as a paragraph in each.
Future cross-links to wire up. Once the entries above exist, add related links from this entry to: migraine, medication-overuse-headache, cluster-headache, cervicogenic-headache, biofeedback, amitriptyline. Also: a sleep entry, a hydration entry, a screen-ergonomics entry, and any stress-management entry β referenced in the lifestyle layer of the protocol section.
Citation library note. The NestoriucEtAl2008 ref was added with the title of the migraine-biofeedback paper by the same authors; the DOI 10.1037/0022-006X.76.3.379 resolves correctly to the TTH meta-analysis (J Consult Clin Psychol 76(3):379β396), which is the paper actually cited. Title metadata in the library should be corrected on a follow-up pass; the cite resolution itself is right.
Dream tier. Overall score computes to ~42 by the weighted-applicability formula in dream-narrative.md Β§1, so the narrative is obligatory. Lever picked is relief / not-being-conned, not aspiration β TTH is a recurrent condition, not a transformation entry. Dek and tagline are both written to compress the MOH-trap reveal, since that is the single sharpest payoff in the entry and the one most underserved by the OTC market's own messaging.
Tension Headache
Costs almost nothing β a few dollars of painkillers per pack and, if prevention is needed, a cheap generic pill.
Knowing the right move on a tension headache β and the analgesic threshold that quietly turns occasional headaches into daily ones β buys back days that used to vanish into a dull head and a foggy afternoon.
Mostly knowing the rules β one pill early in the attack, and an honest count of how many days a month you reach for it. Real but light.
Multiple Cochrane reviews, a European specialist guideline, and decades of headache research line up behind the same management playbook.
A running tension headache half-shuts down concentration. Treating one well, and breaking the loop that produces frequent ones, gives the deep-work hours back.
Living with a head that hurts most days quietly drags mood and anxiety; cutting the frequency lifts both.
Fewer afternoons lost to a dull pressing head means a small but real lift in usable energy.
Headaches disturb sleep, and bad sleep feeds headaches; managing one steadies the other, modestly.